Contrasting Incannex Healthcare (NASDAQ:IXHL) and Tvardi Therapeutics (NASDAQ:TVRD)

Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Incannex Healthcare and Tvardi Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare 2 0 1 0 1.67
Tvardi Therapeutics 1 0 6 1 2.88

Incannex Healthcare currently has a consensus price target of $18.00, suggesting a potential upside of 832.64%. Tvardi Therapeutics has a consensus price target of $9.40, suggesting a potential upside of 754.55%. Given Incannex Healthcare’s higher possible upside, equities research analysts plainly believe Incannex Healthcare is more favorable than Tvardi Therapeutics.

Earnings & Valuation

This table compares Incannex Healthcare and Tvardi Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incannex Healthcare $90,000.00 269.13 -$19.30 million ($1.24) -1.56
Tvardi Therapeutics $7.14 million 2.06 -$18.21 million ($2.68) -0.41

Tvardi Therapeutics has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Incannex Healthcare has a beta of 7, suggesting that its stock price is 600% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Institutional & Insider Ownership

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 9.1% of Incannex Healthcare shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Incannex Healthcare and Tvardi Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Incannex Healthcare N/A -19.86% -18.80%
Tvardi Therapeutics N/A -145.40% -91.11%

Summary

Incannex Healthcare beats Tvardi Therapeutics on 7 of the 13 factors compared between the two stocks.

About Incannex Healthcare

(Get Free Report)

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing investigational medicines, including cannabinoid-based combination therapies and psychedelic-assisted treatments. Its research focuses on conditions with significant unmet medical needs; its products are in development and are not established as approved treatments. The company’s pipeline has included IHL-42X, a combination of dronabinol and acetazolamide being studied for obstructive sleep apnea, as well as programs targeting inflammatory conditions and traumatic brain injury.

About Tvardi Therapeutics

(Get Free Report)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.

Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.